Health
Freiburg immunologists decipher anti-cancer drug’s mode of operation – News-Medical.net
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University…
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface…
-
Noosa News21 hours agoToyah Cordingley’s accused killer Rajwinder Singh had sand ‘scattered’ throughout car, Cairns court hears
-
Noosa News7 hours agoHockey coach in Arana Hills charged with grooming and sexual offences against teenage girls
-
Noosa News22 hours agoAcademics hit back after leading universities oppose key environmental legislation
-
Noosa News23 hours agoLand care spreading far and wide